iBio, Inc.
For the period ended Jun 30, 2025. Filed Sep 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 5, 2025
IBIO$0.78-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – June 30, 2025 and 2024
Consolidated Balance Sheets** **
(In Thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · June 30, · · June 30, | ||||||
| · · 2025 · · 2024 | ||||||
| · · · · | ||||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $8,582 | | $14,210 | ||
| Subscription receivable | | | 105 | | | — |
| Promissory note receivable and accrued interest | | | — | | | 713 |
| Prepaid expenses and other current assets | | 1,034 | | 749 | ||
| Total Current Assets | | 9,721 | | 15,672 | ||
| | | | | | ||
| Restricted cash | | | 210 | | | 215 |
| Promissory note receivable | | | 1,098 | | | 1,081 |
| Finance lease right-of-use assets, net of accumulated amortization | | 68 | | 339 | ||
| Operating lease right-of-use asset | | | 2,051 | | | 2,401 |
| Fixed assets, net of accumulated depreciation | | 3,163 | | 3,632 | ||
| Intangible assets, net of accumulated amortization | | | 6,848 | | | 5,368 |
| Security deposits | | | 26 | | | 26 |
| Total Assets | | $23,185 | | $28,734 | ||
| | | | | | ||
| Liabilities and Stockholders' Equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $2,188 | | $358 | ||
| Accrued expenses | | 1,345 | | 2,028 | ||
| Finance lease obligations - current portion | | | 53 | | | 299 |
| Operating lease obligation - current portion | | | 490 | | | 436 |
| Equipment financing payable - current portion | | | 64 | | | 178 |
| Term promissory note - current portion | | | 766 | | | 218 |
| Insurance premium financing payable | | | — | | | 123 |
| Contract liabilities | | | 1,200 | | | 200 |
| Total Current Liabilities | | 6,106 | | 3,840 | ||
| | | | | | ||
| Finance lease obligations - net of current portion | | | — | | | 53 |
| Operating lease obligation - net of current portion | | | 2,199 | | | 2,688 |
| Equipment financing payable - net of current portion | | | — | | | 63 |
| Term promissory note - net of current portion | | | — | | | 766 |
| Total Liabilities | | 8,305 | | 7,410 | ||
| | | | | | ||
| Stockholders' Equity | | | | | ||
| Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2025 and June 30, 2024; 0 shares issued and outstanding as of June 30, 2025 and June 30, 2024 | | — | | — | ||
| Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2025 and June 30, 2024; 19,349,201 and 8,623,676 shares issued and outstanding as of June 30, 2025 and June 30, 2024, respectively | | 19 | | | 9 | |
| Additional paid-in capital | | 347,085 | | | 335,162 | |
| Accumulated deficit | | | (332,224) | | | (313,847) |
| Total Stockholders’ Equity | | 14,880 | | 21,324 | ||
| Total Liabilities and Stockholders' Equity | | $23,185 | | $28,734 | ||
| | | | | | | |
| Share and per share data have been adjusted for June 30, 2024 presented to reflect the one-for-twenty (1:20) reverse stock split effective November 29, 2023. | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.